Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
NCT ID: NCT00978705
Last Updated: 2009-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
19 participants
INTERVENTIONAL
2007-11-30
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Cultured Autologous Keratinocytes for Burn Wound Healing
NCT00832156
Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area
NCT03686449
Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment
NCT03675568
Treatment of Patients With Skin Burns Using Keratinocytes and Skin Fibroblasts
NCT04485962
Biological Skin Graft With Keratinocyte-stem Cell Co-cultre for Burn Patients
NCT05652816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous cultured keratinocyte cell
3x10\^7 cell/ vial
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* More than 30% TBSA of second degree burn or more than 10% TBSA of third degree burn
* Must provide signed informed consent prior to participation in any study-related procedures
Exclusion Criteria
* Part of the facial cosmetic surgery cost
* Hypersensitivity reactions in patients with bovine proteins
* Hypersensitivity reactions in patients with Gentamycin
* Pregnancy or lactation
1 Year
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosolution Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Modern Cell and Tissue Technology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wook Chun, MD
Role: PRINCIPAL_INVESTIGATOR
Hangang Sacred Heart Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangang Sacred Heart Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCTT-KRH-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.